Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Agendia Bv
Agendia's MammaPrint Receives Prestigious Award From Dutch Innovation Platform
July 11th, 2008
Agendia BV, a world leader in gene expression analysis-based diagnostics, is pleased to announce that the company recently received a prestigious award for its groundbreaking MammaPrint(R) test from the Dutch Innovation Platform. MammaPrint, a 70-gene signature diagnostic test that predicts high or low risk of breast cancer tumor recurrence, was chosen out of more than 150 entries as the most pioneering healthcare initiative and will have the distinguished honor of being actively supported at a national level by the Dutch government. "We are honored that the value of MammaPrint has been recognized at a governmental level for its significant impact on the management of...
Source: Health Business Week (2008-07-11)
|
